BioLab Holdings Expands Workforce to Strengthen Operations
Hiring Growth Reflects Commitment to Research, Quality and Compliance
BioLab Holdings, Inc. is thrilled to announce its ongoing expansion and dedication to job creation and economic impact for its surrounding communities. As a medical manufacturer specializing in wound care products, BioLab has successfully added 37 skilled professionals to its teams in pivotal departments, enhancing its ability to deliver superior wound care solutions and exceptional service to patients, providers, and insurance companies.
In a statement, BioLab President Jaime Leija expressed, "We're investing in people to power BioLab’s next chapter, expanding research capacity, elevating quality assurance, and strengthening corporate compliance, so we can deliver advanced wound care solutions to more patients while adhering to the highest regulatory standards. This approach is fundamental to our sustainability and local economic contributions."
New Leadership Enhances Quality Assurance
BioLab Holdings welcomes Chris Silvers as the new Vice President of Quality Assurance. Since joining in May, Chris has been tasked with the critical responsibility of creating and executing a robust global quality strategy, ensuring alignment with BioLab’s overall strategic goals. With over 25 years of experience in the medical device industry, Chris's expertise in regulatory affairs and quality assurance will strengthen BioLab's operational excellence.
Chris has an impressive track record of managing regulatory strategies and overseeing quality systems, which have facilitated product innovation and significant market growth. His leadership has been crucial in navigating successful FDA and international audits, fostering quality manufacturing operations, product development, and readiness for compliance.
Chief Compliance Officer Joins to Enhance Corporate Compliance
Joining the team in May as Chief Compliance Officer, Dixon Terry plays an essential role in ensuring corporate compliance across all departments. With over three decades of experience in the biopharmaceutical and medical device industries, Dixon is skilled at promoting adherence to federal and state health care program requirements. His vast experience includes leading compliance functions within large corporations and start-up organizations alike.
Dixon’s career highlights include key leadership roles at prominent companies such as Amgen, where he directed teams across various aspects of clinical development, sales, and compliance.
Innovating Research Strategies
Another noteworthy new addition is Research Strategist Weston Quinn, who recently completed his Ph.D. in Molecular Genetics at Arizona State University. His focus on Cis-regulatory programs is particularly relevant to wound healing research. Weston's fresh insights will advance the company's commitment to developing cutting-edge wound care products, showcasing BioLab’s dedication to professional growth and a culture of innovation.
2025 Hires Strengthening BioLab’s Core
In addition to its leadership expansions, BioLab has hired new professionals across various domains, including:
Quality: Quality Engineering Supervisor Nick Swanson, Complaint & QMS Analyst Jennifer Battle, Quality Auditor Brenda Sparks.
Research & Product Development: Product Development Engineer Drew Norowski, Project Manager Breanna Kirchhardt.
Corporate Compliance: Compliance Manager Kessa Chanthavongsa.
Operations: Director of Supply Chain Operations Austin Feldman, Senior Buyer Kymber MacDonald.
Sales & Marketing: Regional Sales Manager Brennan Lagemann, Marketing Coordinator Collete Roth.
Human Resources: HR Operations & Compliance Manager Shelly Courter.
Finance & Accounting: Senior Cost Accountant Pete Wolfrom, Director of Financial Planning & Analysis Jim Doroz.
Information Technology: Chief Technology Officer Klint Price.
This comprehensive hiring strategy underlines BioLab’s commitment to operational excellence and its aspiration to better serve patients and healthcare providers with top-notch product offerings.
About BioLab Holdings, Inc.
BioLab Holdings, Inc. specializes in manufacturing advanced wound care solutions utilizing human tissue allografts derived from amniotic membranes. Their products, including Membrane Wrap Lite™, Tri-Membrane Wrap™, and others, are designed to aid in wound protection effectively. The organization is committed to innovation, education, and superior service, ensuring the highest quality of care in its offerings.
Frequently Asked Questions
What is BioLab Holdings known for?
BioLab Holdings is known for manufacturing wound care products using amniotic membrane tissue that aids in the healing process.
Who is the new VP of Quality Assurance at BioLab?
Chris Silvers has been appointed as the new VP of Quality Assurance, bringing over 25 years of industry experience.
What is the focus of Research Strategist Weston Quinn?
Weston Quinn focuses on molecular genetics and wound healing research, enhancing the company’s innovation capabilities.
How many employees has BioLab added to its team?
BioLab has added 37 new employees across various departments to strengthen its operations.
What does BioLab prioritize in its hiring strategy?
BioLab prioritizes hiring skilled professionals who can contribute to research, quality assurance, and overall company growth.
